Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.
News|Articles|July 24, 2025
- Vol. 26/No. 9
- Volume 26
- Issue 9
Cellular Therapies Begin to Make Their Mark in Solid Tumors
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.
Advertisement
Advertisement
Cellular therapies such as CAR T-cell agents and bispecific T-cell engagers (BiTEs) have had a major effect on the treatment landscape of patients with hematologic malignancies with 7 agents earning indications across subtypes of leukemia and lymphoma, as well as multiple myeloma.1 In the solid tumor realm, investigators are pushing hard to integrate this class of agents into multiple disease settings, with some notable successes already.
Related to this article
Dana M. Chase, MD, joins Angeles Alvarez Secord, MD, MHSc, to discuss mocertatug rezetecan in gynecologic malignancies.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
Hamza Hashmi, MD, discusses the evolving role and implementation of CAR T-cell therapy in early relapsed/refractory multiple myeloma.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Jill Gilbert, MD, discusses the journey of lifelong learning in hematology/oncology.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
Maurie Markman, MD, discusses conflicts of interest in cancer care.
Advertisement
Advertisement